Successful treatment with gemtuzumab ozogamicin monotherapy in a pediatric patient with resistant relapse of acute myeloid leukemia
There are few therapeutic options in relapsed or refractory acute myeloid leukemia patients. CD33 antigen is expressed on approximately 90% of myeloblasts, and gemtuzumab ozogamicin, as a monoclonal antibody directed against the CD33 surface antigen, may be a good target for these patients. H...
Shranjeno v:
| Principais autores: | , , , , |
|---|---|
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
Hacettepe University Institute of Child Health
2009-02-01
|
| Serija: | The Turkish Journal of Pediatrics |
| Online dostop: | https://turkjpediatr.org/article/view/2260 |
| Oznake: |
Brez oznak, prvi označite!
|